For prostate cancer, prostate-specific membrane antigen (PSMA) has currently emerged as an attractive target for theranostic development to help individualize prostate cancer treatment and evaluate the effectiveness of treatment and cancer recurrence [5,6]. The gene discussed is FOLH1; the disease is Familial prostate cancer.